Clinical trials: Refractory Classic Hodgkin Lymphoma
Hodgkin's Lymphoma
A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma
Phase II study to assess the efficacy of 6 cycles of oral JAK1/2 inhibitor ruxolitinib in patients with advanced Hodgkin's lymphoma for whom no curative option is available.
- Trial name
- HIJAK (NCT01877005)
- Testing
- Ruxolitinib
- Where
- 10 sites in Belgium, France
- Volunteers
- 33 people
- Sponsor
- The Lymphoma Academic Research Organisation
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Grade 1 Follicular Lymphoma
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
This phase I/Ib trial studies the side effects and best dose of ibrutinib when given together with pembrolizumab and to see how well they work in treating patients with non-Hodgkin lymphoma that has come back or does not respond…
- Conditions
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
- Trial name
- NCT02950220
- Testing
- Ibrutinib, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Kami Maddocks
Classical Hodgkin Lymphoma, Classical Hodgkin Lymphoma Recurrent
Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma
Classical Hodgkin's Lymphoma (cHL) is a rare but highly treatable malignancy of the immune system, primarily affecting young adults.
- Conditions
- Classical Hodgkin Lymphoma, Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory
- Trial name
- LH_BIO (NCT06822855)
- Where
- 12 sites in Italy
- Volunteers
- 755 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Classic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma
Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma
This phase II trial studies how well nivolumab and brentuximab vedotin work after stem cell transplant in treating patients with high-risk classical Hodgkin lymphoma that has come back (recurrent) or does not respond to treatment…
- Conditions
- Classic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
- Trial name
- NCT03057795
- Testing
- Brentuximab Vedotin, Laboratory Biomarker Analysis, Nivolumab
- Where
- 6 sites in United States
- Volunteers
- 62 people
- Sponsor
- City of Hope Medical Center
Hodgkin Lymphoma, Adult, Relapsed Hodgkin's Disease, Adult
RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT
This is a multicenter, observational real world study with prospective follow up that will evaluate the treatment approach in patients with relapsed/refractory cHL who undergo ASCT in Argentina.
- Conditions
- Hodgkin Lymphoma, Adult, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma
- Trial name
- NCT04776265
- Testing
- Evaluation of therapeutical approach after ASCT
- Where
- 15 sites in Argentina
- Volunteers
- 100 people
- Sponsor
- Grupo Argentino de Tratamiento de la Leucemia Aguda
Hodgkin Lymphoma
Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
The goal of this clinical trial is to study the combination of nivolumab and axatilimab in patients with relapsed/refractory classical Hodgkin Lymphoma. This study will mainly look at if the combination works as expected.
- Trial name
- NAHL (NCT05723055)
- Testing
- Axatilimab, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- University of Utah
Autologous Stem Cell Transplant, Classic Hodgkin Lymphoma
MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
This is a Phase 2 single arm study to evaluate efficacy and safety of Pembrolizumab before with BEAM ASCT followed by Pembrolizumab maintenance for 1 year.
- Trial name
- NCT06377540
- Testing
- Pembrolizumab, Autologous stem cell transplant, Carmustine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
This phase I trial studies the side effects and best dose of CPI-613 when given together with bendamustine hydrochloride in treating patients with relapsed or refractory T-cell non-Hodgkin lymphoma or Hodgkin lymphoma.
- Conditions
- Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Trial name
- NCT02168140
- Testing
- 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences
Leukemia, Lymphoma
Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer
RATIONALE: Giving chemotherapy before a donor peripheral blood stem cell transplant helps stop both the growth of cancer cells and the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00301860
- Testing
- anti-thymocyte globulin, filgrastim, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of California, San Francisco
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed
This phase I trial tests the safety and best dose of CC-486 (an oral form of azacitidine) when given together with nivolumab in treating patients with Hodgkin lymphoma that does not respond (refractory) to PD1-based immunotherapy…
- Trial name
- NCT05162976
- Testing
- Nivolumab, Oral Azacitidine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- City of Hope Medical Center
Relapsed or Refractory Classical Hodgkin Lymphoma
Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of sabestomig (AZD7789) in patients with relapsed/refractory classical Hodgkin Lymphoma (r/r cHL).
- Trial name
- NCT05216835
- Testing
- Sabestomig (AZD7789)
- Where
- 14 sites in United States, Canada and 5 more
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Relapsed Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
The goal of this phase 2 trial is to test the safety and efficacy of azacitidine when given together with PD-1 therapy in treating patients with relapsed/refractory classic Hodgkin lymphoma.
- Trial name
- NCT06190067
- Testing
- Azacitidine Plus PD-1 therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Navy General Hospital, Beijing
Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
This phase II study is designed to determine the clinical efficacy of PD-1 blockade, using the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475), administered as consolidation therapy after autologous stem cell transplant…
- Conditions
- Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma
- Trial name
- NCT02362997
- Testing
- Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 82 people
- Sponsor
- Dana-Farber Cancer Institute
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
This phase II trial studies the effect of brentuximab vedotin and nivolumab in treating patients with classic Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory) that have been previously…
- Trial name
- NCT05039073
- Testing
- Brentuximab Vedotin, Hematopoietic Cell Transplantation, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Emory University
Classical Hodgkin Lymphoma, Relapsed Cancer
Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
This is a phase 2 open-label study to test the safety and effectiveness of combining pembrolizumab and bendamustine in patients with relapsed (cancer that has come back or started getting worse) or refractory (cancer that is not…
- Conditions
- Classical Hodgkin Lymphoma, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT04510636
- Testing
- Pembrolizumab, Bendamustine Hydrochloride
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Hodgkins Lymphoma
Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)
This is a Phase 1b, open-label, multi-center study comprising a lead-in phase and an expansion phase. The lead-in phase is a multiple-dose, randomized, parallel-arm, pharmacokinetic and pharmacodynamic study of avelumab as a…
- Trial name
- NCT02603419
- Testing
- Avelumab
- Where
- 13 sites in United States, Italy and 1 more
- Volunteers
- 34 people
- Sponsor
- Pfizer
Hodgkin Lymphoma
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
The study is being conducted to compare JS004 plus Toripalimab with Investigator-Selected Chemotherapy in Patients with PD-(L)1 monoclonal antibody refractory Classic Hodgkin Lymphoma (cHL)
- Trial name
- NCT06170489
- Testing
- JS004 in combination with Toripalimab, Bendamustine or gemcitabine
- Where
- China
- Volunteers
- 185 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Hodgkin Lymphoma, Adult
BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant
A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin's Lymphoma, Followed by Brentuximab Vedotin Consolidation…
- Trial name
- BRESELIBET (NCT04378647)
- Testing
- Induction with Brentuximab vedotin (BV), Induction without Brentuximab Vedotin, Consolidation with Brentuximab Vedotin
- Where
- 19 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Diffuse Large B-Cell Lymphoma
Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in combination with various agents for the treatment of Relapsed/Refractory (R/R)…
- Trial name
- Javelin DLBCL (NCT02951156)
- Testing
- Avelumab, Utomilumab, Rituximab
- Where
- 29 sites in United States, Australia and 6 more
- Volunteers
- 29 people
- Sponsor
- Pfizer